• OPEN AN ACCOUNT
Indian Indices
Nifty
22,502.00 35.90
(0.16%)
Sensex
74,005.94 88.91
( 0.12%)
Bank Nifty
48,199.50 83.85
( 0.17%)
Nifty IT
33,438.75 56.90
( 0.17%)
Global Indices
Nasdaq
16,685.97 -12.35
(-0.07%)
Dow Jones
40,003.59 134.21
(0.34%)
Hang Seng
19,553.61 177.08
(0.91%)
Nikkei 225
38,787.38 -132.88
(-0.34%)
Forex
USD-INR
83.47 0.01
(0.01%)
EUR-INR
90.76 0.22
(0.25%)
GBP-INR
105.79 0.36
(0.34%)
JPY-INR
0.54 0.00
(0.51%)

EQUITY - MARKET SCREENER

Paramount Cosmetics (India) Ltd
Industry :  Personal Care - Indian
BSE Code
ISIN Demat
Book Value()
507970
INE143I01013
42.0634398
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
73.21
19.91
EPS(TTM)
Face Value()
Div & Yield %
0.56
10
0
 

avro india ltd
Shilpa Medicare's Telangana facility gets Europe GMP Approval
Apr 17,2024
The said unit of Shilpa Medicare is engaged in the manufacture, testing and distribution of sterile Injections and non-sterile tablets and Capsule finished dosage forms in the US, Europe and rest of the world markets.

The previous EU – GMP inspection for this facility was in January 2020.

Earlier, the company’s unit 4, Jadcherla, Telangana, facility was inspected by AGES, Austria from 22 January, 2024 until 26 January, 2024.

Following a successful inspection, the said unit has been issued GMP Certification from Ages, Austria.

This inspection will facilitate continued supply of medicines for commercial distribution to various countries of the European Union from this unit.

Shilpa Medicare is a global brand in manufacturing and supplying of API and formulation globally in different regulated markets.

The company’s consolidated net profit stood at Rs 4.58 crore in Q3 FY24 as compared with net loss of Rs 6.62 crore posted in Q3 FY23. Net sales stood at Rs 286.48 crore in Q3 FY24, up 9.1% year on year.

The scrip rallied 6.14% to ends at Rs 540.45 on Tuesday, 16 April 2024. The domestic market is shut on account of Ram Navami.